SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases & Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
Preventing Dementia Together: A Data-Driven Approach to Early Detection and Risk Reduction
Sep 15, 2025
Dementia, including Alzheimer’s Disease (AD), is one of the most urgent global health challenges of our time. With around 900,000 people currently living with dementia in the UK, and global cases projected to reach 139 million by 2050, the need for early identification and prevention is more urgent than ever1.
At IQVIA, we are committed to advancing the science and strategy behind dementia care. Our approach aligns with the latest findings from the Lancet Commission’s 2024 report2, which offers new hope through prevention, diagnosis, and treatment.
Driving Early Detection: IQVIA’s Innovations in Alzheimer’s Care
IQVIA is actively reshaping the Alzheimer’s disease landscape through a multifaceted approach that integrates cutting-edge diagnostics, clinical trial innovation, and strategic partnerships. This includes advancing the use of blood-based biomarkers, such as pTau217, pTau231, GFAP, and Neurofilament light (NfL), to facilitate early detection and monitoring in primary care settings. IQVIA also supports biotech sponsors in designing robust clinical trials by leveraging these biomarkers as endpoints, enabling more precise and scalable assessments of disease-modifying therapies. Collaborations such as the Davos Alzheimer’s Collaborative further amplify their impact, combining global data analytics with health system preparedness to accelerate early-stage interventions and improve outcomes across the AD care continuum3,4.
IQVIA has played a pivotal role in shaping the future of Alzheimer’s care in the UK through its leadership in a national project focused on early AD pathway transformation. By collaborating with Integrated Care Systems (ICSs), IQVIA identified critical gaps in diagnostic consistency, biomarker utilisation, and service integration. Recommendations advocate for the adoption of scalable blood-based biomarkers, standardised GP training, and age-agnostic referral protocols to enable earlier and more accurate diagnoses. IQVIA also emphasised the importance of preparing for amyloid-targeting therapies by enhancing infusion infrastructure and genetic testing workflows. This work supports a system-wide shift toward proactive, equitable, and data-driven dementia care, aligning scientific innovation with real-world implementation.
While early detection is critical, prevention through lifestyle changes offers another powerful tool in the fight against dementia.
Modifiable Risk Factors: A Preventive Lens
The Lancet Commission emphasises the critical role of modifiable risk factors in dementia prevention. The 2024 Lancet update identifies 14 key contributors, including two newly recognised risks: high Low-Density Lipoprotein (LDL) cholesterol and untreated vision loss. These factors span across different life stages:
| Early life | Midlife (ages 18-65) | Late Life (65+) |
|---|---|---|
| 1. Less education | 2. Hearing Loss | 12. Social Isolation |
| 3. High LDL cholesterol (new in 2024) | 13. Air Pollution | |
| 4. Depression | 14. Untreated vision loss (new in 2024) | |
| 5. Traumatic brain injury | ||
| 6. Physical inactivity | ||
| 7. Diabetes | ||
| 8. Smoking | ||
| 9. Hypertension | ||
| 10. Obesity | ||
| 11. Excessive alcohol consumption |
Collectively, these 14 factors are estimated to contribute to up to 45% of dementia cases globally, if addressed throughout the life course. Tackling them offers a powerful opportunity to delay or even prevent nearly half of all dementia cases2,5.
IQVIA’s research supports integrating these risk factors into predictive profiling models, enabling more personalised, preventive care strategies that align with public health goals and individual needs2,5.
The Lancet Commission outlines practical, evidence-based actions to reduce dementia risk:
IQVIA’s data-driven approach supports public health initiatives that incorporate these interventions, reinforcing the importance of multicomponent strategies tailored to individual needs regardless of genetic predisposition.
Living Well with Dementia and the Promise of Emerging Treatments
For people living with dementia, timely and tailored support following diagnosis can significantly enhance wellbeing. Effective interventions should be person-centred and involve collaboration with families, carers, and support networks. Approaches that help carers cope, especially those addressing emotional and behavioural symptoms, are vital to sustaining quality care and reducing stress.
Livingston et al. (2024) highlights that medications such as cholinesterase inhibitors and memantine may offer benefits for individuals with Alzheimer’s disease and Lewy body dementia. These treatments are generally affordable and can help manage symptoms, though their effectiveness varies from person to person.
There is growing momentum in the development of disease-modifying treatments (DMTs) for Alzheimer’s disease. Some clinical trials involving amyloid-β-targeting antibodies have shown modest benefits in slowing cognitive decline. Beyond amyloid-targeting therapies, a diverse range of DMTs are currently in development, offering hope for more effective and accessible options in the future. This marks an encouraging shift toward more comprehensive and inclusive approaches to dementia care and treatment.
Conclusion: Turning Insight into Action
The convergence of IQVIA’s clinical expertise and the Lancet Commission’s latest findings offers a powerful roadmap for tackling dementia. By prioritising early identification, addressing modifiable risk factors, and supporting those affected, we can reshape the future of dementia care making it more preventive, personalised, and impactful.
Dementia is not inevitable, and together, we can change its trajectory. At IQVIA, we are pioneering a future where early detection, personalised prevention, and equitable access to care are the norm. But we cannot do it alone.
Whether you are a healthcare provider, policymaker, researcher, or advocate, your role is vital. Let’s collaborate to:
- Integrate blood-based biomarkers into routine care for earlier, more accurate diagnoses.
- Empower communities with education and tools to address modifiable risk factors across the life course.
- Support carers and patients with person-centred interventions and emerging treatments.
- Drive system-wide change by aligning innovation with real-world implementation.
Act now to be part of a data-driven, compassionate approach to dementia prevention and care. Together, we can make dementia more manageable and increasingly preventable.
Connect with IQVIA to explore partnerships, access resources, and advance the future of brain health.
References
- Public Health England. (2021, June 28). Health matters: Midlife approaches to reduce dementia risk. GOV.UK. https://www.gov.uk/government/publications/health-matters-midlife-approaches-to-reduce-dementia-risk/health-matters-midlife-approaches-to-reduce-dementia-risk
- Livingston, Gill et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, Vol 404, Issue 10452, 572 – 628. The Lancet. https://doi.org/10.1016/S0140-6736(24)01296-0[1](https://chronicdisease.org/wp-content/uploads/2024/12/Lancet-2024.pdf)
- Hugo, P., & Bieniek, M. (2024). Alzheimer’s disease clinical trials: Innovative laboratory solutions to accelerate progress. IQVIA Laboratories. https://labs.iqvia.com
- Bieniek, M., & Veerman, G. (2025). Advancing Alzheimer’s disease therapies: How biotech sponsors can accelerate clinical development of early stage interventions. IQVIA Biotech. https://www.iqviabiotech.com/-/media/biotech/pdfs/library/white-papers/advancing-alzheimers-disease-therapies-white-paper-iqvia-biotech.pdf
- Alzheimer’s Association. (2025, July 31). Research advances from the 2025 Alzheimer’s Association International Conference (AAIC®). AAIC 2025 Overview News Release. https://aaic.alz.org/downloads2025/AAIC2025OverviewNewsRelease-final.pdf